Aortic intramural hematoma

Revision as of 17:04, 25 February 2019 by Mmir (talk | contribs)
Jump to navigation Jump to search

WikiDoc Resources for Aortic intramural hematoma

Articles

Most recent articles on Aortic intramural hematoma

Most cited articles on Aortic intramural hematoma

Review articles on Aortic intramural hematoma

Articles on Aortic intramural hematoma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Aortic intramural hematoma

Images of Aortic intramural hematoma

Photos of Aortic intramural hematoma

Podcasts & MP3s on Aortic intramural hematoma

Videos on Aortic intramural hematoma

Evidence Based Medicine

Cochrane Collaboration on Aortic intramural hematoma

Bandolier on Aortic intramural hematoma

TRIP on Aortic intramural hematoma

Clinical Trials

Ongoing Trials on Aortic intramural hematoma at Clinical Trials.gov

Trial results on Aortic intramural hematoma

Clinical Trials on Aortic intramural hematoma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Aortic intramural hematoma

NICE Guidance on Aortic intramural hematoma

NHS PRODIGY Guidance

FDA on Aortic intramural hematoma

CDC on Aortic intramural hematoma

Books

Books on Aortic intramural hematoma

News

Aortic intramural hematoma in the news

Be alerted to news on Aortic intramural hematoma

News trends on Aortic intramural hematoma

Commentary

Blogs on Aortic intramural hematoma

Definitions

Definitions of Aortic intramural hematoma

Patient Resources / Community

Patient resources on Aortic intramural hematoma

Discussion groups on Aortic intramural hematoma

Patient Handouts on Aortic intramural hematoma

Directions to Hospitals Treating Aortic intramural hematoma

Risk calculators and risk factors for Aortic intramural hematoma

Healthcare Provider Resources

Symptoms of Aortic intramural hematoma

Causes & Risk Factors for Aortic intramural hematoma

Diagnostic studies for Aortic intramural hematoma

Treatment of Aortic intramural hematoma

Continuing Medical Education (CME)

CME Programs on Aortic intramural hematoma

International

Aortic intramural hematoma en Espanol

Aortic intramural hematoma en Francais

Business

Aortic intramural hematoma in the Marketplace

Patents on Aortic intramural hematoma

Experimental / Informatics

List of terms related to Aortic intramural hematoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]


Overview

  • It may occur as a primary event in hypertensive patients in whom there is spontaneous bleeding from vasa vasorum into the media or may be caused by a penetrating atherosclerotic ulcer.
  • Intramural hematoma may also develop as a result of blunt chest trauma with aortic wall injury.
  • Thought to begin with the rupture of the vasa vasorum, the blood vessels that penetrate the outer half of the aortic media from the adventitia and arborize within the media to supply the aortic wall.
  • The hematoma propagates along the media layer of the aorta.
  • Consequently, intramural hematoma weakens the aorta and may progress either to outward rupture of the aortic wall or to inward disruption of the intima, the latter leading to communicating aortic dissection.
  • Unlike aortic dissection, no intimal flap is present.
  • If it involves the ascending aorta, treatment is surgical to prevent rupture or progression to a classic aortic dissection.
  • Conservative management is indicated for aortic intramural hematomas of the descending aorta.

Historical Perspective

  • [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
  • In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
  • In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
  • The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Clinical Features

Differentiating [disease name] from other Diseases

  • [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

  • The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
  • In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

  • Patients of all age groups may develop [disease name].
  • [Disease name] is more commonly observed among patients aged [age range] years old.
  • [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected with [disease name] than [gender 2].
  • The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

  • There is no racial predilection for [disease name].
  • [Disease name] usually affects individuals of the [race 1] race.
  • [Race 2] individuals are less likely to develop [disease name].

Risk Factors

  • Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • The majority of patients with [disease name] remain asymptomatic for [duration/years].
  • Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
  • If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
  • Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

  • The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • [Disease name] is usually asymptomatic.
  • Symptoms of [disease name] may include the following:
  • [symptom 1]
  • [symptom 2]
  • [symptom 3]
  • [symptom 4]
  • [symptom 5]
  • [symptom 6]

Physical Examination

  • Patients with [disease name] usually appear [general appearance].
  • Physical examination may be remarkable for:
  • [finding 1]
  • [finding 2]
  • [finding 3]
  • [finding 4]
  • [finding 5]
  • [finding 6]

Laboratory Findings

  • There are no specific laboratory findings associated with [disease name].
  • A [positive/negative] [test name] is diagnostic of [disease name].
  • An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
  • Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

  • There are no [imaging study] findings associated with [disease name].
  • [Imaging study 1] is the imaging modality of choice for [disease name].
  • On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

  • [Disease name] may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

  • There is no treatment for [disease name]; the mainstay of therapy is supportive care.
  • The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
  • [Medical therapy 1] acts by [mechanism of action 1].
  • Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for [disease name].
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
  • [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

  • There are no primary preventive measures available for [disease name].
  • Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

Examples

Images courtesy of RadsWiki

Contrast enhanced CT: Aortic intramural hematoma


Contrast enhanced CT: Aortic intramural hematoma


Contrast enhanced CT: Aortic intramural hematoma


Contrast enhanced CT: Aortic intramural hematoma


Contrast enhanced CT: Aortic intramural hematoma


Contrast enhanced CT: Aortic intramural hematoma



See also

External Links

References


Template:WikiDoc Sources CME Category::Cardiology